WO1995008626A1
(en)
*
|
1993-09-20 |
1995-03-30 |
The Regents Of The University Of Colorado |
Strategy for the production of rna from immobilized templates
|
ES2340532T3
(en)
|
2001-06-05 |
2010-06-04 |
Curevac Gmbh |
MRNA WITH AN INCREASED G / C CONTENT THAT CODIFIES FOR A BACTERIAL ANTIGEN AND USING THE SAME.
|
DE10162480A1
(en)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
The application of mRNA for use as a therapeutic agent against tumor diseases
|
US7074596B2
(en)
|
2002-03-25 |
2006-07-11 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse mRNA cap analogues
|
DE10229872A1
(en)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immune stimulation through chemically modified RNA
|
DE10335833A1
(en)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfection of blood cells with mRNA for immune stimulation and gene therapy
|
DE102004042546A1
(en)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Combination therapy for immune stimulation
|
DE102005023170A1
(en)
|
2005-05-19 |
2006-11-23 |
Curevac Gmbh |
Optimized formulation for mRNA
|
EP1926835B1
(en)
|
2005-09-21 |
2014-12-31 |
BioArray Solutions Ltd. |
Message abundance and allele copy number determination using ivt with single-stranded primer-promoter-selector constructs
|
US8114636B2
(en)
*
|
2006-02-10 |
2012-02-14 |
Life Technologies Corporation |
Labeling and detection of nucleic acids
|
JP2009544754A
(en)
|
2006-07-28 |
2009-12-17 |
アプライド バイオシステムズ, エルエルシー |
Dinucleotide MRNA cap analog
|
DE102006035618A1
(en)
|
2006-07-31 |
2008-02-07 |
Curevac Gmbh |
New nucleic acid useful as immuno-stimulating adjuvant for manufacture of a composition for treatment of cancer diseases e.g. colon carcinomas and infectious diseases e.g. influenza and malaria
|
DE102006061015A1
(en)
|
2006-12-22 |
2008-06-26 |
Curevac Gmbh |
Process for the purification of RNA on a preparative scale by HPLC
|
DE102007001370A1
(en)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-encoded antibodies
|
US20080194416A1
(en)
*
|
2007-02-08 |
2008-08-14 |
Sigma Aldrich |
Detection of mature small rna molecules
|
ES2500515T3
(en)
|
2007-06-19 |
2014-09-30 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse phosphorothioate analogues of the messenger RNA cap
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
CA2710534C
(en)
|
2008-01-31 |
2018-09-04 |
Curevac Gmbh |
Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant
|
PL215513B1
(en)
|
2008-06-06 |
2013-12-31 |
Univ Warszawski |
New borane phosphate analogs of dinucleotides, their application, RNA particle, method of obtaining RNA and method of obtaining peptides or protein
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
EP2449113B8
(en)
|
2010-07-30 |
2015-11-25 |
CureVac AG |
Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
WO2012121973A1
(en)
*
|
2011-03-04 |
2012-09-13 |
Life Technologies Corporation |
Compounds and methods for conjugation of biomolecules
|
WO2013059475A1
(en)
|
2011-10-18 |
2013-04-25 |
Life Technologies Corporation |
Alkynyl-derivatized cap analogs, preparation and uses thereof
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
EP2623121A1
(en)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
CN104321432B
(en)
|
2012-03-27 |
2018-08-10 |
库瑞瓦格股份公司 |
Include the artificial nucleic acid molecule of 5 ' TOP UTR
|
ES2660459T3
(en)
|
2012-03-27 |
2018-03-22 |
Curevac Ag |
Artificial Nucleic Acid Molecules
|
AU2013242404B2
(en)
|
2012-03-27 |
2018-08-30 |
CureVac SE |
Artificial nucleic acid molecules for improved protein or peptide expression
|
US20150306249A1
(en)
|
2012-05-25 |
2015-10-29 |
Curevac Gmbh |
Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
|
CN109045289A
(en)
|
2013-02-22 |
2018-12-21 |
库瑞瓦格股份公司 |
Vaccine inoculation and the combination for inhibiting PD-1 approach
|
SG11201510748PA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Composition and vaccine for treating lung cancer
|
CA2915730A1
(en)
|
2013-08-21 |
2015-02-26 |
Karl-Josef Kallen |
A combination rsv/influenza a vaccine
|
JP6896421B2
(en)
|
2013-08-21 |
2021-06-30 |
キュアバック アーゲー |
Respiratory syncytial virus (RSV) vaccine
|
WO2015024667A1
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Method for increasing expression of rna-encoded proteins
|
CA2915712A1
(en)
|
2013-08-21 |
2015-02-26 |
Margit SCHNEE |
Rabies vaccine
|
RU2016109938A
(en)
|
2013-08-21 |
2017-09-26 |
Куревак Аг |
COMPOSITION AND VACCINE FOR TREATMENT OF PROSTATE CANCER
|
ES2806575T3
(en)
|
2013-11-01 |
2021-02-18 |
Curevac Ag |
Modified RNA with decreased immunostimulatory properties
|
WO2015101415A1
(en)
|
2013-12-30 |
2015-07-09 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
SG11201603144QA
(en)
|
2013-12-30 |
2016-07-28 |
Curevac Ag |
Artificial nucleic acid molecules
|
AU2014375404C1
(en)
|
2013-12-30 |
2020-11-19 |
CureVac Manufacturing GmbH |
Methods for RNA analysis
|
CA2935878C
(en)
|
2014-03-12 |
2023-05-02 |
Curevac Ag |
Combination of vaccination and ox40 agonists
|
CA2936286A1
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Ag |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
MX2016016170A
(en)
|
2014-06-10 |
2017-03-28 |
Curevac Ag |
Methods and means for enhancing rna production.
|
DE202015010000U1
(en)
|
2014-12-12 |
2023-07-03 |
CureVac SE |
Artificial nucleic acid molecules for improved protein expression
|
EP3233113A1
(en)
|
2014-12-16 |
2017-10-25 |
CureVac AG |
Ebolavirus and marburgvirus vaccines
|
AU2015373404B2
(en)
|
2014-12-30 |
2021-09-09 |
CureVac SE |
Artificial nucleic acid molecules
|
WO2016165825A1
(en)
|
2015-04-13 |
2016-10-20 |
Curevac Ag |
Method for producing rna compositions
|
WO2016165831A1
(en)
|
2015-04-17 |
2016-10-20 |
Curevac Ag |
Lyophilization of rna
|
JP6912384B2
(en)
|
2015-04-22 |
2021-08-04 |
キュアバック アーゲー |
RNA-containing compositions for the treatment of cancer diseases
|
SG11201708681SA
(en)
|
2015-04-30 |
2017-11-29 |
Curevac Ag |
Method for in vitro transcription using an immobilized restriction enzyme
|
SG11201708867UA
(en)
|
2015-04-30 |
2017-11-29 |
Curevac Ag |
Immobilized poly(n)polymerase
|
EP3294885B1
(en)
|
2015-05-08 |
2020-07-01 |
CureVac Real Estate GmbH |
Method for producing rna
|
US11559570B2
(en)
|
2015-05-15 |
2023-01-24 |
CureVac SE |
Prime-boost regimens involving administration of at least one mRNA construct
|
WO2016184575A1
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
EP3297682B1
(en)
|
2015-05-20 |
2021-07-14 |
CureVac AG |
Dry powder composition comprising long-chain rna
|
EP3744843A1
(en)
|
2015-05-29 |
2020-12-02 |
CureVac Real Estate GmbH |
A method for producing and purifying rna, comprising at least one step of tangential flow filtration
|
EP4098743A1
(en)
|
2015-05-29 |
2022-12-07 |
CureVac AG |
Method for adding cap structures to rna using immobilized enzymes
|
WO2016203025A1
(en)
|
2015-06-17 |
2016-12-22 |
Curevac Ag |
Vaccine composition
|
EP4239080A3
(en)
|
2015-07-01 |
2023-11-01 |
CureVac Manufacturing GmbH |
Method for analysis of an rna molecule
|
US10501768B2
(en)
|
2015-07-13 |
2019-12-10 |
Curevac Ag |
Method of producing RNA from circular DNA and corresponding template DNA
|
US20200085852A1
(en)
|
2015-08-05 |
2020-03-19 |
Curevac Ag |
Epidermal mrna vaccine
|
EP3332019B1
(en)
|
2015-08-07 |
2019-12-18 |
CureVac AG |
Process for the in vivo production of rna in a host cell
|
CN108138187B
(en)
|
2015-08-10 |
2022-07-19 |
库瑞瓦格房地产有限公司 |
Method for increasing replication of circular DNA molecules
|
CN108026537B
(en)
|
2015-08-28 |
2022-02-08 |
库瑞瓦格股份公司 |
Artificial nucleic acid molecules
|
EP3362576A1
(en)
|
2015-10-12 |
2018-08-22 |
CureVac AG |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
US20180312545A1
(en)
|
2015-11-09 |
2018-11-01 |
Curevac Ag |
Optimized nucleic acid molecules
|
WO2017081110A1
(en)
|
2015-11-09 |
2017-05-18 |
Curevac Ag |
Rotavirus vaccines
|
WO2017108087A1
(en)
|
2015-12-21 |
2017-06-29 |
Curevac Ag |
Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
|
EP3701963A1
(en)
|
2015-12-22 |
2020-09-02 |
CureVac AG |
Method for producing rna molecule compositions
|
WO2017109161A1
(en)
*
|
2015-12-23 |
2017-06-29 |
Curevac Ag |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
EP3414340B1
(en)
|
2016-02-12 |
2023-08-09 |
CureVac SE |
Method for analyzing rna
|
EP3417069A1
(en)
|
2016-02-15 |
2018-12-26 |
CureVac AG |
Method for analyzing by-products of rna in vitro transcription
|
SG11201806340YA
(en)
|
2016-02-17 |
2018-09-27 |
Curevac Ag |
Zika virus vaccine
|
US11920174B2
(en)
|
2016-03-03 |
2024-03-05 |
CureVac SE |
RNA analysis by total hydrolysis and quantification of released nucleosides
|
WO2017162297A1
(en)
|
2016-03-24 |
2017-09-28 |
Curevac Ag |
Immobilized inorganic pyrophosphatase (ppase)
|
EP3445392A1
(en)
|
2016-04-22 |
2019-02-27 |
CureVac AG |
Rna encoding a tumor antigen
|
EP3448427A1
(en)
|
2016-04-29 |
2019-03-06 |
CureVac AG |
Rna encoding an antibody
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|
WO2017191264A1
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Nucleic acid molecules and uses thereof
|
EP3452086A1
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Influenza mrna vaccines
|
US20180126003A1
(en)
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
EP3464619A1
(en)
|
2016-05-25 |
2019-04-10 |
CureVac AG |
Novel biomarkers
|
US20190381180A1
(en)
|
2016-06-09 |
2019-12-19 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
WO2017212009A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
US20190336611A1
(en)
|
2016-06-09 |
2019-11-07 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
EP3468609A1
(en)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Cationic carriers for nucleic acid delivery
|
SG10201913631TA
(en)
|
2016-08-19 |
2020-03-30 |
Curevac Ag |
Rna for cancer therapy
|
BR112019008481A2
(en)
|
2016-10-26 |
2020-03-03 |
Curevac Ag |
LIPID NANOPARTICLE MRNA VACCINES
|
US11279923B2
(en)
|
2016-11-28 |
2022-03-22 |
Curevac Ag |
Method for purifying RNA
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
CN110582304A
(en)
|
2016-12-08 |
2019-12-17 |
库尔维科公司 |
RNA for treating or preventing liver disease
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
EP3595715A1
(en)
|
2017-03-17 |
2020-01-22 |
CureVac AG |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
JP2020513824A
(en)
|
2017-03-24 |
2020-05-21 |
キュアバック アーゲー |
NUCLEIC ACID ENCODING CRISPR-RELATED PROTEIN AND USE THEREOF
|
US20230064106A1
(en)
|
2017-05-17 |
2023-03-02 |
Curevac Real Estate Gmbh |
Method for determining at least one quality parameter of an rna sample
|
BR112019028280A2
(en)
|
2017-07-04 |
2020-07-14 |
Curevac Ag |
nucleic acid molecules
|
EP3673069A1
(en)
|
2017-08-22 |
2020-07-01 |
CureVac AG |
Bunyavirales vaccine
|
MX2020003995A
(en)
|
2017-10-19 |
2020-07-22 |
Curevac Ag |
Novel artificial nucleic acid molecules.
|
US11692002B2
(en)
|
2017-11-08 |
2023-07-04 |
CureVac SE |
RNA sequence adaptation
|
US11931406B2
(en)
|
2017-12-13 |
2024-03-19 |
CureVac SE |
Flavivirus vaccine
|
SG11202005760PA
(en)
|
2017-12-21 |
2020-07-29 |
Curevac Ag |
Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
|
EP3773702A2
(en)
|
2018-04-05 |
2021-02-17 |
CureVac AG |
Novel yellow fever nucleic acid molecules for vaccination
|
SG11202008225PA
(en)
|
2018-04-17 |
2020-11-27 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
WO2020002525A1
(en)
|
2018-06-27 |
2020-01-02 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
MX2020013148A
(en)
|
2018-06-28 |
2021-03-02 |
CureVac RNA Printer GmbH |
Bioreactor for rna in vitro transcription.
|
TW202039534A
(en)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
Kras variant mrna molecules
|
SG11202106666UA
(en)
|
2018-12-21 |
2021-07-29 |
Curevac Ag |
Methods for rna analysis
|
CN113453707A
(en)
|
2018-12-21 |
2021-09-28 |
库瑞瓦格股份公司 |
RNA for malaria vaccine
|
WO2020161342A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
IL293571A
(en)
|
2020-02-04 |
2022-08-01 |
Curevac Ag |
Coronavirus vaccine
|